Literature DB >> 27412873

Increased Circulating Tissue Inhibitor of Metalloproteinase-2 Is Associated With Resistant Hypertension.

Andrea R Sabbatini1, Natalia R Barbaro1, Ana Paula de Faria1, Rodrigo Modolo1, Alessandra Mileni V Ritter1, Claudio Pinho2, Rivadavio Fernandes Batista Amorim3, Vanessa Fontana1, Heitor Moreno4.   

Abstract

Resistant hypertension (RH) is associated with organ damage and cardiovascular risk. Evidence suggests the involvement of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinase 2 (TIMP-2) in hypertension and in cardiovascular remodeling. The aim of this study was to assess the levels of MMP-2 and TIMP-2 in RH and its relation with organ damage, including arterial stiffness and cardiac hypertrophy. MMP-2 and TIMP-2 levels were compared among 19 patients with normotension (NT), 116 with nonresistant hypertension (HTN) and 116 patients with resistant HTN (RH). MMP-2 levels showed no differences among NT, HTN, and RH groups, while TIMP-2 levels were higher in RH compared with HTN and NT groups (90.0 [76.1-107.3] vs 70.1 [57.7-88.3] vs 54.7 [40.9-58.1] ng/mL, P<.01), respectively. MMP-2/TIMP-2 ratio was reduced in the RH group compared with the HTN and NT groups (2.7 [1.9-3.4] vs 3.3 [2.6-4.2] vs 4.9 [4.5-5.3], P<.01), respectively. No associations were found between MMP-2 levels, TIMP-2, and MMP-2/TIMP-2 ratio with cardiac hypertrophy and arterial stiffness in the RH and HTN groups. Finally, in a regression analysis, reduced MMP-2/TIMP-2 ratio and increased TIMP-2 levels were independently associated with RH. The present findings provide evidence that TIMP-2 is associated with RH and might be a possible biomarker for screening RH patients. ©2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27412873      PMCID: PMC8031610          DOI: 10.1111/jch.12865

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  44 in total

1.  Inhibitory effect of acetylsalicylic acid on matrix metalloproteinase - 2 activity in human endothelial cells exposed to high glucose.

Authors:  Manuela Nicolae; Magdalena Tircol; Dorin Alexandru
Journal:  J Cell Mol Med       Date:  2005 Oct-Dec       Impact factor: 5.310

2.  Vascular smooth muscle cell motility: From migration to invasion.

Authors:  Sherif F Louis; Peter Zahradka
Journal:  Exp Clin Cardiol       Date:  2010

3.  Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus.

Authors:  Damiano Rizzoni; Enzo Porteri; Carolina De Ciuceis; Intissar Sleiman; Luigi Rodella; Rita Rezzani; Silvia Paiardi; Rossella Bianchi; Giuseppina Ruggeri; Gianluca E M Boari; Maria Lorenza Muiesan; Massimo Salvetti; Francesca Zani; Marco Miclini; Enrico Agabiti Rosei
Journal:  Hypertension       Date:  2005-02-21       Impact factor: 10.190

4.  Enhancement of matrix metalloproteinase 2 and 9 inhibitory action of minocycline by aspirin: an approach to attenuate outcome of acute myocardial infarction in diabetes.

Authors:  Lokesh K Bhatt; Addepalli Veeranjaneyulu
Journal:  Arch Med Res       Date:  2014-03-04       Impact factor: 2.235

Review 5.  Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and meta-analysis.

Authors:  Chiara Marchesi; Francesco Dentali; Eleonora Nicolini; Andrea M Maresca; Mazahir H Tayebjee; Marcus Franz; Luigina Guasti; Achille Venco; Ernesto L Schiffrin; Gregory Y H Lip; Anna M Grandi
Journal:  J Hypertens       Date:  2012-01       Impact factor: 4.844

6.  Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness.

Authors:  Carmel M McEniery; Sharon Wallace; Zahid Dakham; Pawan Pulsalkar; Pusalkar Pusalkar; Kaisa Maki-Petaja; Mike J Ashby; John R Cockcroft; Ian B Wilkinson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-11-18       Impact factor: 8.311

Review 7.  Translating Koch's postulates to identify matrix metalloproteinase roles in postmyocardial infarction remodeling: cardiac metalloproteinase actions (CarMA) postulates.

Authors:  Rugmani Padmanabhan Iyer; Lisandra E de Castro Brás; Yu-Fang Jin; Merry L Lindsey
Journal:  Circ Res       Date:  2014-02-28       Impact factor: 17.367

8.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

9.  Increased Circulating Tissue Inhibitor of Metalloproteinase-2 Is Associated With Resistant Hypertension.

Authors:  Andrea R Sabbatini; Natalia R Barbaro; Ana Paula de Faria; Rodrigo Modolo; Alessandra Mileni V Ritter; Claudio Pinho; Rivadavio Fernandes Batista Amorim; Vanessa Fontana; Heitor Moreno
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-07-14       Impact factor: 3.738

10.  Improvement in All-Cause Mortality With Blood Pressure Control in a Group of US Veterans With Drug-Resistant Hypertension.

Authors:  Omid Fatemi; Cristobal Goa; Charles Faselis; Peter Kokkinos; Vasilios Papademetriou
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-10-06       Impact factor: 3.738

View more
  2 in total

Review 1.  Arterial (Aortic) Stiffness in Patients with Resistant Hypertension: from Assessment to Treatment.

Authors:  James E Sharman; Pierre Boutouyrie; Stéphane Laurent
Journal:  Curr Hypertens Rep       Date:  2017-01       Impact factor: 5.369

2.  Increased Circulating Tissue Inhibitor of Metalloproteinase-2 Is Associated With Resistant Hypertension.

Authors:  Andrea R Sabbatini; Natalia R Barbaro; Ana Paula de Faria; Rodrigo Modolo; Alessandra Mileni V Ritter; Claudio Pinho; Rivadavio Fernandes Batista Amorim; Vanessa Fontana; Heitor Moreno
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-07-14       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.